P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e44640da
10.1097/01.hs9.0000971016.44640.da